The portfolio maintains a sizable cost advantage over competitors, priced within the least expensive fee quintile among peers.
VanEck Pharmaceutical ETF PPH
- NAV / 1-Day Return 86.78 / +0.30 %
- Total Assets 496.5 Mil
-
Adj. Expense Ratio
- Expense Ratio 0.360%
- Distribution Fee Level —
- Share Class Type —
- Category Health
- Investment Style Large Blend
- Min. Initial Investment —
- Status Open
- TTM Yield 1.87%
- Turnover 22%
USD | NAV as of Apr 27, 2024 | 1-Day Return as of Apr 27, 2024, 1:00 AM GMT+0
Morningstar’s Analysis PPH
Will PPH outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 64.8
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 11.73 | 58.6 Mil | Healthcare |
Novo Nordisk A/S ADR | 9.83 | 49.1 Mil | Healthcare |
Johnson & Johnson | 6.56 | 32.8 Mil | Healthcare |
Merck & Co Inc | 6.23 | 31.1 Mil | Healthcare |
AbbVie Inc | 5.88 | 29.4 Mil | Healthcare |
AstraZeneca PLC ADR | 5.59 | 27.9 Mil | Healthcare |
Novartis AG ADR | 4.93 | 24.6 Mil | Healthcare |
McKesson Corp | 4.70 | 23.4 Mil | Healthcare |
Cencora Inc | 4.69 | 23.4 Mil | Healthcare |
Haleon PLC ADR | 4.68 | 23.4 Mil | Healthcare |